MRC Technology and Institut Pasteur of Shanghai

Chinese Academy of Sciences collaborate on antibody drug development


On March 7th, MRC Technology (Medical Research Council Technology transfer charity, UK) and Institut Pasteur of Shanghai, Chinese Academy of Sciences - IPS-CAS signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.


Monoclonal antibody-based drugs have been established as one of the most successful therapeutic strategies for the treatment of infectious diseases, cancers and autoimmune diseases. “The promise of immune check-point antibodies and broadly neutralizing antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important”, said Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies.

Read more on IPS-CAS website: here